knowcompoundssertraline
Specimen compound organic compoundPlate I
Sertraline

- Formula
- C17H17Cl2N
- Molar mass
- 306.236 g/mol
- ChEBI
- CHEBI:9123
- PubChem CID
- 68617
- InChIKey
- VGKDLMBJGBXTGI-SJCJKPOMSA-N
↑ raised 1 finding · – no difference found
01 · the evidence, ordered
What the evidence says
- Moderate
- 2
- Very limited
- 1
Sertraline
36 compounds on the outer ring, not drawn
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
02 · findings
What sertraline moved, and by how much
- OR odds ratio. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
- Tumour necrosis factor alpha concentrationMoved: no difference foundEvidence: ModeratePaper: PMID 426465942026
- Who
- adults treated with sertraline for depressive disorders, pooled across trials with mixed comorbidities including coronary heart disease and chronic kidney disease
- Dose studied
- not reported
Overall, the pooled results suggest that sertraline did not significantly alter circulating levels of IL-6, IL-10, or TNF-α across the included studies.”
Quoted verbatim from Sertraline as an Antidepressant and Inflammatory Cytokines in Depressive Disorders: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.meta-analysisPermalink - Interleukin-6 concentrationMoved: no difference foundEvidence: ModeratePaper: PMID 426465942026
- Who
- adults treated with sertraline for depressive disorders, pooled across trials with mixed comorbidities including coronary heart disease and chronic kidney disease
- Dose studied
- not reported
Overall, the pooled results suggest that sertraline did not significantly alter circulating levels of IL-6, IL-10, or TNF-α across the included studies.”
Quoted verbatim from Sertraline as an Antidepressant and Inflammatory Cytokines in Depressive Disorders: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.meta-analysisPermalink - Congenital cardiovascular malformation incidence (offspring)Moved: raisesEffect, as reportedOR1.36[1.06 to 1.74]Evidence: Very limitedPaper: PMID 277705422017
- Who
- Infants of pregnant women exposed to sertraline in the first trimester; meta-analysis of 12 cohort studies
- Dose studied
- not reported
Pregnant women who used sertraline in the first trimester had a statistically significant increased risk of infant cardiovascular-related malformations (OR = 1.36; 95% CI = 1.06-1.74; I2 = 64.4%; n = 12) as well as atrial and/or ventricular septal defects (OR = 1.36, 95% CI = 1.06-1.76; I2 = 62.2%; n = 8).”
Quoted verbatim from Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.meta-analysisPermalink
No row matches these filters.
No dose is advised.
- OR odds ratio. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
03 · identity
Structure
- Charge
- 0
- SMILES
- [H][C@@]1(c2ccc(Cl)c(Cl)c2)CC[C@H](NC)c2ccccc21
04 · figures · 1 plate
Plates

fig. 4Sertraline · MS2 [M+H]+ LC-ESI-QFT positive · MassBank MSBNK-ACES_SU-AS000376 (ACESx, CC BY)
05 · the record
Sources
760
papers screened for sertraline
- admitted
- 2
- read and discarded
- 137
- not read yet
- 621
- Documented interactions
- None reported
Sources cited
2 papers · 3 findings